Skip to content
JournalsWorldThe Global Research Discovery Platform
SCHOLARLY PUBLICATION ✓ Open Access

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1 H -indol-5-yl)-7 H -pyrrolo[2,3- d ]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng, Arthur Y. L. Shu, Stuart P. Romeril, Seth W. Grant, William Hoi Hong Li, Dirk A. Heerding, Elisabeth A. Minthorn, Thomas Mencken, Charity L. Atkins, Qi Liu, Sridhar K. Rabindran, Rakesh Kumar, Xuan Hong, Aaron S. Goetz, Thomas B. Stanley, J. David Taylor, Scott Sigethy, Ginger H. Tomberlin, Annie M. Hassell, Kirsten M. Kahler, Lisa M. Shewchuk, Robert T. Gampe

📄 Abstract

Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors. Through screening and lead optimization using the human PERK crystal structure, we discovered compound 38 (GSK2606414), an orally available, potent, and selective PERK inhibitor. Compound 38 inhibits PERK activation in cells and inhibits the growth of a human tumor xenograft in mice.

📤 Share this page

Found this useful? Share it with your network.

✓ Link copied! Paste it on ResearchGate / Academia.edu